5 Reasons the Obesity Drug Market Remains Strong

Summary

Thoughts on the Market: Episode Summary

Title: 5 Reasons the Obesity Drug Market Remains Strong
Host/Author: Morgan Stanley
Release Date: June 5, 2025

Morgan Stanley's podcast, Thoughts on the Market, in its episode titled "5 Reasons the Obesity Drug Market Remains Strong," delves into the burgeoning landscape of obesity medications, particularly focusing on GLP1 (Glucagon-like peptide-1) therapies. Terence Flynn, Morgan Stanley's US Pharma and Biotech Analyst, spearheads the discussion, highlighting the pivotal factors driving global growth in this sector.

---

Market Growth Projections

Terence Flynn opens the discussion by positioning the obesity medicine market at a critical juncture. He states, “The market for obesity medicines is at an inflection point and today I'll focus on what's driving the next stage of global growth” (00:00). Emphasizing the transformative nature of GLP1 drugs, Flynn forecasts substantial market expansion, estimating the total addressable market (TAM) for obesity medications to reach $150 billion globally by 2035. This projection delineates approximately $80 billion from the U.S. and $70 billion from international markets, marking a significant uptick from the previous 2024 forecast of $105 billion. This expansion underscores a growing recognition of opportunities beyond the U.S. borders.

---

Current Adoption Rates and Future Projections

Presently, adoption rates of GLP1 treatments are modest, with about 2-3% within the eligible obesity population in the U.S. and roughly 1% internationally (00:00). Flynn anticipates a surge in these figures to 20% in the U.S. and 10% globally. This anticipated increase is attributed to several driving factors, which Flynn elaborates on throughout the episode.

---

Five Drivers of Market Strength

1. Improved Supply and Production

After experiencing shortages, the supply constraints for GLP1 medications have notably improved. Flynn remarks, “Supply constraints have improved and the drug makers are investing aggressively to increase production” (00:00). This increased production capacity is pivotal in meeting the growing demand and facilitating wider accessibility.

2. Broadening Clinical Applications

Emerging data reveals that obesity drugs have applications extending beyond weight management. Flynn highlights, “New data show that obesity drugs have broader clinical applications,” including treatments for conditions such as coronary heart disease, stroke, hypertension, kidney disease, and sleep apnea. There's also potential in combating Alzheimer’s disease, neuropsychiatric conditions, and cancer, broadening the therapeutic landscape of these medications (00:00).

3. Expansion of Coverage

As obesity drugs receive approvals for treating additional diseases, insurance coverage is expected to expand. Flynn states, “Coverage will expand as obesity drugs are approved to treat diseases beyond obesity.” Furthermore, public healthcare coverage through Medicare is projected to grow, providing a broader safety net for patients seeking these treatments (00:00).

4. Development of Pill Form Medications

The shift from injectable forms to pill-based obesity medications represents a significant advancement. Flynn notes, “Some drug makers are successfully developing obesity drugs in pill form instead of injectables.” Pills offer greater ease of administration and the potential for rapid global distribution, thereby enhancing patient adherence and market penetration (00:00).

5. Next-Generation Medications

Innovation continues with the development of next-generation obesity drugs that boast higher efficacy, novel mechanisms of action, and more convenient dosing schedules. Flynn asserts, “Drug makers are also developing next gen medications with even higher efficacy, new mechanisms of action and more convenient, less frequent dosing,” which are crucial for sustained patient engagement and competitive advantage in the market (00:00).

---

Broader Impacts on Other Sectors

Flynn anticipates that the widespread adoption of GLP1 therapies will have ripple effects beyond the biopharmaceutical industry. He mentions significant anticipated impacts on medical technology, healthcare services, and consumer sectors such as food, beverages, and fashion. Changes in patient diets and lifestyles, influenced by effective obesity treatments, could potentially reshape market dynamics across these diverse sectors (00:00).

---

Conclusion

In summary, the obesity drug market, spearheaded by GLP1 medications, is poised for substantial growth driven by improved supply chains, broadened clinical applications, expanded insurance coverage, innovative drug formulations, and next-generation therapeutic advancements. These factors collectively not only bolster the biopharmaceutical landscape but also herald transformative changes across various interconnected industries.

Terence Flynn concludes the episode by reaffirming the expansive potential of GLP1 adoption over the next decade, emphasizing its far-reaching implications beyond traditional healthcare markets (00:00).

---

Disclaimer: The information provided in this summary is based on the transcript of the podcast episode and is intended for informational purposes only. It does not constitute financial, legal, or medical advice.

Transcript

[A]

Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's US Pharma and biotech analyst. The market for obesity medicines is at an inflection point and today I'll focus on what's driving the next stage of global growth. It's Thursday, June 5th at 2pm in New York. GLP1 medicines have been viewed by many stakeholders as one of the most transformative medications on the market today. They've exploded in popularity over the last few years and become game changers for many people who take them. These drugs have large cap biopharma companies racing to innovate. They've had ripple effects on food, fitness and fashion. They truly are a major market force. And now we're on the cusp of a significant broadening of use of these medicines. Currently, the US is the largest consumer in the world of GLP1s. But new versions of these medicines suggest that this market will extend beyond the US to significantly larger numbers of patients globally. On our estimates, the total addressable market, or TAM, for obesity medications should reach $150 billion globally by 2035, with approximately $80 billion from the US and $70 billion from international markets. Now, this marks a meaningful increase from our 2024 forecast of $105 billion and reflects a greater appreciation of opportunities outside of the U.S. we think obesity drug adoption will likely accelerate as patients and providers become more familiar with the new products and as manufacturers address hurdles in production, distribution and access. Current adoption rates of GLP1 treatments within the eligible obesity population are about 2 to 3%. This is in the US and roughly 1% in the rest of the world. Now, when we look out further, we anticipate these figures to surge to 20% and 10%, respectively. Really, driven by five things. First, after a period of shortages, supply constraints have improved and the drug makers are investing aggressively to increase production. Second, new data show that obesity drugs have broader clinical applications. They can be used to treat coronary heart disease, stroke, hypertension, kidney disease, or even sleep apnea. They could also potentially fight Alzheimer's disease, neuropsychiatric conditions, and even cancer. Third, we think coverage will expand as obesity drugs are approved to treat diseases beyond obesity. Public health care coverage through Medicare should also broaden based on these expected approvals. Fourth, some drug makers are successfully developing obesity drugs in pill form instead of injectables. Pills are, of course, easier to administer and can reach global scale quickly. And finally, drug makers are also developing next gen medications or with even higher efficacy, new mechanisms of action and more convenient, less frequent dosing. All in all, we think that over the next decade, broader GLP1 adoption will extend well beyond biopharma. We expect significant impacts on medical technology, healthcare services, and consumer sectors like food, beverages and fashion, where changes in patient diets could reshape market dynamics. Thanks so much for listening and for watching.

[B]

Thanks.

[A]

If you enjoy the show, please leave us a review wherever you listen and share thoughts on the market with a friend or colleague today.

[C]

The preceding content is informational only and based on information available when created. It is not an offer or solicitation, nor is it tax or legal advice. It does not consider your financial circumstances and objectives and may not be suitable for you.